RENEWAL : REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus
© 2022. The Author(s)..
Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson's disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Alzheimer's research & therapy - 14(2022), 1 vom: 11. Nov., Seite 169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Brien, John T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.11.2022 Date Revised 29.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13195-022-01103-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348826591 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348826591 | ||
| 003 | DE-627 | ||
| 005 | 20231226041202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13195-022-01103-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348826591 | ||
| 035 | |a (NLM)36369100 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Brien, John T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RENEWAL |b REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.11.2022 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson's disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Chouliaras, Leonidas |e verfasserin |4 aut | |
| 700 | 1 | |a Sultana, Janet |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, John-Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Ballard, Clive |e verfasserin |4 aut | |
| 700 | 0 | |a RENEWAL Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Aarsland, Dag |e investigator |4 oth | |
| 700 | 1 | |a Blanc, Frederic |e investigator |4 oth | |
| 700 | 1 | |a Boeve, Bradley |e investigator |4 oth | |
| 700 | 1 | |a Brooks, David J |e investigator |4 oth | |
| 700 | 1 | |a Chaudhuri, K Ray |e investigator |4 oth | |
| 700 | 1 | |a Cummings, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Feldman, Howard H |e investigator |4 oth | |
| 700 | 1 | |a Flicker, Leon |e investigator |4 oth | |
| 700 | 1 | |a Galvin, James E |e investigator |4 oth | |
| 700 | 1 | |a Grosset, Donald G |e investigator |4 oth | |
| 700 | 1 | |a Ikeda, Manabu |e investigator |4 oth | |
| 700 | 1 | |a Kohlhaas, Susan |e investigator |4 oth | |
| 700 | 1 | |a Lawlor, Brian |e investigator |4 oth | |
| 700 | 1 | |a Lemstra, Afina W |e investigator |4 oth | |
| 700 | 1 | |a Leroi, Iracema |e investigator |4 oth | |
| 700 | 1 | |a Londos, Elisabet |e investigator |4 oth | |
| 700 | 1 | |a Leverenz, James B |e investigator |4 oth | |
| 700 | 1 | |a Lewis, Simon |e investigator |4 oth | |
| 700 | 1 | |a McKeith, Ian |e investigator |4 oth | |
| 700 | 1 | |a Mills, Roger |e investigator |4 oth | |
| 700 | 1 | |a Oakley, Richard |e investigator |4 oth | |
| 700 | 1 | |a Richardson, Jill |e investigator |4 oth | |
| 700 | 1 | |a Sabbagh, Marwan |e investigator |4 oth | |
| 700 | 1 | |a Skidmore, John |e investigator |4 oth | |
| 700 | 1 | |a Svennigsson, Per |e investigator |4 oth | |
| 700 | 1 | |a Tiraboschi, Pietro |e investigator |4 oth | |
| 700 | 1 | |a Weintraub, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Walker, Zuzana |e investigator |4 oth | |
| 700 | 1 | |a Watson, Rosie |e investigator |4 oth | |
| 700 | 1 | |a Weil, Rimona S |e investigator |4 oth | |
| 700 | 1 | |a Williams-Gray, Caroline H |e investigator |4 oth | |
| 700 | 1 | |a Yarnall, Alison |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's research & therapy |d 2009 |g 14(2022), 1 vom: 11. Nov., Seite 169 |w (DE-627)NLM190604069 |x 1758-9193 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:1 |g day:11 |g month:11 |g pages:169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13195-022-01103-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 1 |b 11 |c 11 |h 169 | ||